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S ex segregation in competitive sports isregarded as fair. Before puberty, boys
and girls hardly differ in height, muscle and
bone mass. Pubertal testosterone exposure
leads to an ultimate average greater height
in men of 12–15 centimeters, larger bones,
greater muscle mass, increased strength and
higher hemoglobin levels. Post-pubertal
androgen ablation reverses, at least in part,
previous anabolic effects of testosterone on
muscle,1 bone mineral density and hemo-
globin, but the bones remain longer and have
a wider diameter. As testosterone administra-
tion produces a dose-dependent increase
in muscle mass and maximal voluntary
strength,2,3 exogenous androgens are banned
as performance-enhancing drugs.4 Men with
testosterone deficiency are allowed to receive
testosterone replacements which do not raise
blood testosterone levels above the normal
male range.5,6
A recent paper highlights the historical case
of a Dutch female athlete (1926–2007) out-
performing most of her competitors in the
years 1948–1950.7 DNA analysis revealed that
she was 46,XX/46,XY mosaic, with equal
numbers of both genetic cell types. While
having breasts, she also had a degree of facial
hairiness pointing to an excess of circulating
testosterone, likely produced by the presence
of Leydig cell in her gonads on the basis of her
XX/XY mosaicism. On the basis of this case,
the authors have also given attention to the
societal context of sports women becoming
involved in a (public) discussion about their
sex which is an intrusion into their privacy.
The authors advocate that matters of sex of
participants in competitive sports should be
settled before athletes enter the arena, and this
will be elaborated below.
Prior to the year 2000, genotyping was the
means of determining sex for competition in
sports. Chromosomal sex alone is not a par-
ticularly adequate indicator for the purpose
of ensuring fair competition, however. In
humans, there is no solid evidence that the
pattern of sex chromosomes has a direct effect
on muscle mass and strength. Rather, the
influence is indirect through determination
of the nature of the embryonic gonadal anla-
gen (testes or ovaries), the hormonal pro-
ducts of these (testosterone and estradiol)
and the quantitative relationship between
those products. In sports, previous and pre-
sent exposure to androgens is a reasonable
criterion for reducing unfair competition,
for both women and men. So, previous and
present exposure to testosterone should be
the determinant of fair competition between
men and between women, also separating the
two sexes. Changes in fat-free mass, muscle
size, strength and power appear to be assoc-
iated with testosterone dose and achieved
concentrations.8
An issue is the participation in competitive
sports of people with errors of sexual differ-
entiation and also of transsexuals treated with
cross-sex hormones (i.e., female-to-male
transsexuals receiving doses of testosterone
similar in magnitude as men receiving tes-
tosterone replacement). With regard to the
effects of testosterone in transsexuals, the
dividing line is whether sex (re)assignment
has taken place before or after hormonal
puberty. Before puberty, there are no signifi-
cant differences in body composition
between girls and boys, so, in this context only
post-pubertal sex reassignment is relevant.
It has been demonstrated in the rat that
genetic configuration and gonadal status have
no known significant effect on sensitivity to
the biological action of sex steroids.9 Effects
of testosterone in puberty and thereafter are
certainly in part reversible but there is no
definitive information on the extent of this.
It is unknown whether or for how long earlier
effects of androgen exposure carry over after
androgen ablation.10 In a study comparing
muscle surface areas between male-to-female
transsexuals and female-to-male transsex-
uals, we noted a significant difference in the
average, but there was also a considerable
overlap between the two groups before any
hormonal intervention had taken place. In
spite of muscle surface area reduction
induced by androgen deprivation, after 1 year
the mean muscle surface area in male-
to-female transsexuals remained significantly
greater than in untreated female-to-male
transsexuals; again, an almost complete over-
lap was noted between the two groups.
Testosterone administration to female-to-
male transsexuals increased muscle surface
areas significantly, producing a large overlap
with untreated male-to-female transsexuals
but with a significantly lower mean.10
Effects of cross-sex hormones on insulin-like
growth factor and hemoglobin levels par-
alleled changes in muscle surface area.10
Another group of interest is subjects with
disorders of sexual differentiation and other
subjects with a higher-than-normal endogen-
ous production of androgenic–anabolic hor-
mones (such as congenital virilizing adrenal
hyperplasia and polycystic ovarian syn-
drome). There are studies reporting a higher
lean body mass and bone mass in women
with polycystic ovarian syndrome,11–13 but
whether this translates into better perform-
ance in sports is unknown.
For transsexual people, the International
Olympic Committee has drawn a necessarily
arbitrary but reasonable line with regard to
participation of sex-reassigned transsexuals:
sex reassignment must have taken place at
least 2 years earlier. In support of this
decision, in the abovementioned study, we
found that changes in muscle surface area
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were not greater after 3 years of cross-sex hor-
mone administration than after 1 year.10
Hormone treatment must be appropriate
for the reassigned sex (no overdosing of tes-
tosterone in female-to-male transsexuals),
and the reassigned sex must be legally recog-
nized. The International Olympic Committee
policy is not binding for other sports orga-
nizations. Very recently (1 May 2011),
the International Association of Athletics
Federations (IAAF) has adopted revised
guidelines for the participation in sports of
athletes who have undergone sex reassign-
ment. Reassigned transsexuals must notify
the IAAF of their status if they wish to com-
pete with others. This will be dealt with con-
fidentially for the protection of the privacy of
the person, thus avoiding public debate on
the sex of the participant. The person in ques-
tion will be examined by an Expert Medical
Panel of the IAAF assessing the period of time
since the sex reassignment, the athlete’s
androgen levels and the nature, duration
and results of any treatment following sex
reassignment. The results will be reported to
the IAAF which will grant permission if the
medical assessment does not provide indica-
tions of unfair advantage over other female
competitors.
For subjects with hyperandrogenism, on 12
April 2011, the IAAF announced the adoption
of new rules and regulations governing the
eligibility of females with hyperandrogenism
to participate in women’s competition, which
equally have come into force on 1 May 2011
(http://www.iaaf.org/aboutiaaf/news/newsid
559746.html). The approach is similar to
that of transsexuals. Athletes with a hyper-
androgenic disorder report to the IAAF and
will undergo an assessment by the Expert
Medical Panel. The IAAF is of the opinion
that elevated androgen levels originating
from congenital virilizing adrenal hyperpla-
sia or polycystic ovarian syndrome or similar
conditions are no ground for exclusion even
though the associated hyperandrogenism
may provide some advantages to the athlete.
For the time being, the upper limit of accept-
able serum testosterone levels is a level that is
clearly at the lower limit of the normal male
range (10 nmol l21). This position was
adopted because there is no consensus on
the upper range of serum testosterone levels
in women,14 also in view of the problems
with accurate measurements, metabolites,
circadian rhythm and binding proteins etce-
tera of serum testosterone.15 The present
upper limit of acceptable serum testosterone
levels seems a compromise of a committee
that had to come up with formal rules gen-
erally applicable to a population of female
athletes. It might very well be that future
medical research solves the problems of
determining one’s androgen status more
accurately and that a stricter consensus can
be reached what constitutes hyperandrogen-
ism in women. If so, it is likely that the upper
limit of acceptable androgen levels for
female athletes will be lowered. Most practi-
cing physicians will start diagnostic work-up
of hyperandrogenism if serum testosterone
exceeds 3–5 nmol l21.
Eventually, it is illusionary to arrive at
100% fairness in competition on the basis of
serum testosterone levels. First of all, there are
the well-knownmethodological difficulties of
measuring serum testosterone levels reli-
ably.15 Second, serum testosterone levels pro-
vide an indicator of the strength of the
androgen signal, but have limited predictive
value of the biological effects of testosterone
which are codetermined by properties of the
androgen receptor.16 This is exemplified in
people with abnormalities of the androgen
receptor who have high circulating serum
androgen levels, but androgen action is
impaired due to genetically determined abnor-
malities of the molecular properties of the
androgen receptor (androgen insensitivity
syndrome). It seems further appropriate to
place the effects of testosterone in the perspec-
tive of naturally occurring and imponderable
differences in sporting capability between
members of the same sex. Unfair competition
should be prevented as much as possible, and
the above measures of the IAAF are the best
possible at present, but ultimately Nature is
unfair in her endowments of talents for all
walks of life, including sports.
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